ABT - Abbott Laboratories Stock Price, Fair Value and News

104.94USD-1.23 (-1.16%)Market Closed

Market Summary

USD104.94-1.23

Market Closed

-1.16%

ABT Stock Price

View Fullscreen

ABT RSI Chart

ABT Valuation

Market Cap

182.6B

Price/Earnings (Trailing)

32.45

Price/Sales (Trailing)

4.53

EV/EBITDA

22.38

Price/Free Cashflow

37.08

ABT Price/Sales (Trailing)

ABT Profitability

EBT Margin

16.21%

Return on Equity

14.41%

Return on Assets

7.76%

Free Cashflow Yield

2.7%

ABT Fundamentals

ABT Revenue

Revenue (TTM)

40.3B

Rev. Growth (Yr)

2.23%

Rev. Growth (Qtr)

-2.7%

ABT Earnings

Earnings (TTM)

5.6B

Earnings Growth (Yr)

-7.44%

Earnings Growth (Qtr)

-23.46%

Breaking Down ABT Revenue

Last 7 days

-1.3%

Last 30 days

-5.1%

Last 90 days

-6.7%

Trailing 12 Months

-4.8%

How does ABT drawdown profile look like?

ABT Financial Health

Current Ratio

1.6

Debt/Equity

0.32

Debt/Cashflow

0.57

ABT Investor Care

Dividend Yield

1.98%

Dividend/Share (TTM)

2.08

Buy Backs (1Y)

0.12%

Diluted EPS (TTM)

3.21

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	40.3B	0	0	0
2023	41.5B	40.2B	40.0B	40.1B
2022	44.5B	45.5B	45.0B	43.7B
2021	37.3B	40.2B	42.3B	43.1B
2020	32.1B	31.4B	32.2B	34.6B
2019	30.7B	30.9B	31.4B	31.9B
2018	28.4B	29.6B	30.4B	30.6B
2017	22.3B	23.6B	25.1B	27.4B
2016	20.4B	20.6B	20.7B	20.9B
2015	20.4B	20.5B	20.6B	20.4B
2014	19.6B	19.7B	20.0B	20.2B
2013	21.1B	20.7B	20.2B	19.7B
2012	35.1B	30.8B	26.2B	21.5B
2011	36.5B	37.3B	38.4B	38.9B
2010	31.7B	33.1B	34.0B	35.2B
2009	29.5B	29.7B	29.9B	30.8B
2008	26.8B	27.7B	28.6B	29.5B
2007	0	0	0	25.9B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Abbott Laboratories

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 07, 2024	earnhardt lisa d	sold	-2,428,120	106	-22,852	executive vice president
Apr 26, 2024	mcdew darren w	acquired	-	-	1,866	-
Apr 26, 2024	roman michael f	acquired	-	-	1,866	-
Apr 26, 2024	babineaux-fontenot claire	acquired	-	-	1,866	-
Apr 26, 2024	blount sally e.	acquired	-	-	1,866	-
Apr 26, 2024	o'grady michael	acquired	-	-	1,866	-
Apr 26, 2024	gonzalez patricia paola	acquired	-	-	1,866	-
Apr 26, 2024	alpern robert j	acquired	-	-	1,866	-
Apr 26, 2024	starks daniel j	acquired	-	-	1,866	-
Apr 26, 2024	kumbier michelle	acquired	-	-	1,866	-

Which funds bought or sold ABT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	ASSETMARK, INC	added	20.84	2,535,480	12,767,700	0.04%
May 07, 2024	Swiss National Bank	reduced	-4.19	-6,365,220	590,927,000	0.41%
May 07, 2024	ZEVENBERGEN CAPITAL INVESTMENTS LLC	reduced	-0.77	65,614	2,722,040	0.06%
May 07, 2024	JENSEN INVESTMENT MANAGEMENT INC	reduced	-0.02	368,375	11,749,900	0.09%
May 07, 2024	BEACON FINANCIAL GROUP	reduced	-5.33	-24,154	1,054,390	0.12%
May 07, 2024	CHILTON CAPITAL MANAGEMENT LLC	reduced	-3.71	-6,808	1,195,820	0.06%
May 07, 2024	Sather Financial Group Inc	unchanged	-	7,492	237,208	0.02%
May 07, 2024	THOROUGHBRED FINANCIAL SERVICES, LLC	reduced	-12.89	-229,000	2,050,000	0.20%
May 07, 2024	GW HENSSLER & ASSOCIATES LTD	reduced	-5.69	-8,603	320,067	0.02%
May 07, 2024	Foyston, Gordon, & Payne Inc	unchanged	-	43,798	1,386,650	0.33%

Are Funds Buying or Selling ABT?

Are funds buying ABT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ABT

No. of Funds

Unveiling Abbott Laboratories's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	9.01%	156,444,700	SC 13G/A
Jan 26, 2024	blackrock inc.	7.7%	134,061,311	SC 13G/A
Feb 09, 2023	vanguard group inc	8.92%	155,480,794	SC 13G/A
Feb 06, 2023	blackrock inc.	8.0%	139,526,216	SC 13G/A
Feb 09, 2022	vanguard group inc	8.43%	149,152,264	SC 13G/A
Feb 01, 2022	blackrock inc.	7.8%	137,155,602	SC 13G/A
Feb 16, 2021	capital research global investors	4.9%	86,394,199	SC 13G/A
Feb 10, 2021	vanguard group inc	8.31%	147,272,920	SC 13G/A
Jan 29, 2021	blackrock inc.	7.5%	133,426,810	SC 13G/A
Feb 14, 2020	capital research global investors	6.4%	113,689,293	SC 13G/A

Recent SEC filings of Abbott Laboratories

View All Filings

Date Filed	Form Type	Document
May 08, 2024	4	Insider Trading
May 07, 2024	144	Notice of Insider Sale Intent
May 02, 2024	10-Q	Quarterly Report
May 01, 2024	8-K	Current Report
Apr 30, 2024	4	Insider Trading
Apr 30, 2024	4	Insider Trading
Apr 30, 2024	4	Insider Trading
Apr 30, 2024	4	Insider Trading
Apr 30, 2024	4	Insider Trading
Apr 30, 2024	4	Insider Trading

Peers (Alternatives to Abbott Laboratories)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	182.6B	40.3B	-5.05%	-4.82%	32.45	4.53	-2.84%	-3.08%
BDX	67.4B	19.7B	-3.45%	-6.52%	50.6	3.42	4.82%	-17.56%
ALGN	20.6B	3.9B	-14.54%	-9.65%	44.54	5.26	5.72%	46.72%
BAX	18.2B	14.9B	-15.38%	-17.01%	6.88	1.22	2.98%	207.68%
MID-CAP
ATR	10.0B	3.5B	7.32%	25.05%	31.94	2.82	6.16%	35.06%
HSIC	9.3B	12.5B	0.39%	-2.78%	24.01	0.75	-0.61%	-18.83%
BIO	7.6B	2.6B	-17.82%	-26.90%	-23.72	2.94	-6.25%	-68.62%
XRAY	5.8B	3.9B	-13.74%	-32.04%	-61.76	1.47	0.23%	91.03%
AXNX	3.4B	387.1M	-0.59%	20.47%	-215.56	8.87	30.82%	65.57%
PDCO	2.3B	6.6B	-1.26%	-0.69%	11.98	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.92%	-14.34%	-1.85	0.4	7.94%	-1661.78%
ANIK	423.5M	169.3M	11.74%	12.93%	-5.51	2.5	7.49%	-244.90%
ANGO	236.7M	324.0M	-10.59%	-34.33%	-1.23	0.73	-3.19%	-337.41%
APYX	45.4M	52.3M	-10.27%	-60.90%	-2.43	0.87	17.61%	19.28%
AEMD	3.3M	3.7M	-25.00%	250.00%	-0.27	0.88	5.77%	8.23%

Abbott Laboratories News

Latest updates

Abbott Laboratories Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-2.7%	9,964	10,241	10,143	9,978	9,747	10,091	10,410	11,257	11,895	11,468	10,928	10,223	10,456	10,701	8,853	7,328	7,726	8,314	8,076	7,979	7,535
Costs and Expenses	1.4%	8,578	8,461	8,496	8,436	8,238	8,787	8,640	8,881	8,983	9,090	8,382	8,831	8,347	8,269	7,358	6,656	6,968	6,925	6,878	6,773	6,796
S&GA Expenses	8.6%	2,959	2,724	2,723	2,740	2,762	2,973	2,731	2,757	2,787	3,048	2,767	2,726	2,783	2,570	2,302	2,276	2,548	2,413	2,440	2,434	2,478
R&D Expenses	-2.3%	684	700	672	715	654	725	782	684	697	762	672	654	654	698	580	564	578	595	596	577	672
EBITDA Margin	-2.1%	0.21*	0.21*	0.20*	0.20*	0.21*	0.23*	0.25*	0.26*	0.25*	0.24*	0.24*	0.23*	0.22*	0.19*	0.17*	0.16*	0.18*	0.18*	0.18*	-	-
Interest Expenses	-11.3%	141	159	166	159	153	154	141	132	131	131	133	134	135	136	137	134	139	164	167	168	171
Income Taxes	5.0%	211	201	235	261	244	287	323	334	429	338	393	159	250	230	189	-11.00	89.00	191	143	96.00	-40.00
Earnings Before Taxes	-20.0%	1,436	1,795	1,671	1,636	1,562	1,320	1,758	2,352	2,876	2,327	2,493	1,348	2,043	2,388	1,421	526	633	1,240	1,103	1,102	632
EBT Margin	-2.4%	0.16*	0.17*	0.15*	0.16*	0.17*	0.19*	0.21*	0.22*	0.20*	0.19*	0.20*	0.18*	0.17*	0.14*	0.12*	0.11*	0.13*	0.13*	0.12*	-	-
Net Income	-23.5%	1,220	1,594	1,436	1,375	1,318	1,033	1,435	2,018	2,447	1,989	2,100	1,189	1,793	2,162	1,232	537	564	1,049	960	1,006	672
Net Income Margin	-2.2%	0.14*	0.14*	0.13*	0.13*	0.14*	0.16*	0.18*	0.19*	0.17*	0.16*	0.17*	0.16*	0.15*	0.13*	0.10*	0.10*	0.11*	0.12*	0.10*	-	-
Free Cashflow	-72.5%	627	2,283	1,317	696	763	1,716	2,313	2,031	1,744	2,453	2,240	1,715	2,240	3,119	1,570	680	355	1,982	1,547	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-1.0%	72,467	73,214	72,090	73,354	73,794	74,438	72,801	74,202	74,007	21,174	73,795	73,269	72,785	20,955	69,043	68,776	66,777	18,007	68,539	68,427	67,610
Current Assets	-1.3%	22,376	22,670	22,664	23,505	24,377	25,224	24,845	24,956	23,429	24,239	23,492	22,627	21,817	20,441	17,390	17,221	15,498	15,667	16,119	15,195	14,409
Cash Equivalents	-8.9%	6,284	6,896	6,709	7,835	9,161	9,882	9,594	8,937	7,675	9,799	9,302	8,658	8,054	6,838	4,480	4,763	3,377	3,860	4,091	3,137	3,022
Inventory	3.9%	6,827	6,570	6,650	6,871	6,673	6,173	5,734	5,899	5,691	5,157	5,261	5,439	5,387	5,012	5,152	5,202	4,568	4,316	4,392	4,352	4,085
Net PPE	-0.5%	10,107	10,154	9,552	9,449	9,282	9,162	8,689	8,818	8,908	8,959	8,831	8,816	8,832	9,029	8,620	8,343	7,907	8,038	7,825	7,825	7,626
Goodwill	-1.2%	23,400	23,679	23,300	23,300	22,927	22,799	22,284	22,744	23,179	23,200	23,300	23,500	23,384	23,700	23,300	23,100	22,927	23,200	23,046	23,329	23,209
Current Liabilities	1.3%	14,021	13,841	13,042	14,350	14,530	15,489	13,365	12,392	12,647	13,105	12,867	12,614	12,462	11,907	10,257	10,959	10,808	10,863	10,491	9,062	9,113
Short Term Borrowings	-	-	-	-	-	-	-	-	-	-	-	197	199	199	213	208	205	204	201	204	204	201
Long Term Debt	-7.5%	12,576	13,599	14,477	14,562	14,615	14,522	15,297	16,755	17,086	17,296	17,446	17,547	17,489	18,527	18,349	18,184	16,804	16,661	17,639	18,982	18,845
LT Debt, Current	86.1%	2,010	1,080	1,051	2,284	2,285	2,251	1,117	5.00	4.00	754	754	755	756	7.00	6.00	1,290	1,264	1,277	1,254	8.00	8.00
LT Debt, Non Current	-100.0%	-	13,599	14,477	14,562	14,615	14,522	15,297	16,755	17,086	17,296	17,446	17,547	17,489	18,527	18,349	18,184	16,804	16,661	17,639	18,982	18,845
Shareholder's Equity	1.1%	39,043	38,603	37,481	72.00	37,010	36,686	35,675	108	79.00	135	41.00	33,800	33,562	24,145	31,386	79.00	165	31,088	60.00	31,686	23.00
Retained Earnings	1.2%	38,011	37,554	36,920	36,355	35,868	35,257	35,115	34,487	33,295	31,528	30,376	29,053	28,669	27,627	26,266	25,669	25,786	25,847	25,440	25,045	24,613
Accumulated Depreciation	1.4%	11,948	11,779	11,559	11,477	11,323	11,050	10,617	10,640	10,613	10,405	10,351	10,258	9,865	9,764	9,352	9,031	8,800	8,761	8,518	8,506	8,279
Shares Outstanding	0.0%	1,740	1,740	1,740	1,740	1,742	1,753	1,756	1,758	1,762	1,775	1,775	1,779	1,777	1,773	1,774	1,771	1,769	1,768	1,768	-	-
Minority Interest	4.0%	233	224	213	230	222	219	209	226	230	222	216	229	226	219	209	220	209	213	202	208	204
Float	-	-	-	-	185,171	-	-	-	186,105	-	-	-	200,631	-	-	-	157,957	-	-	-	144,957	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-66.3%	1,025	3,038	1,877	1,203	1,143	2,326	2,780	2,410	2,065	3,067	2,701	2,128	2,637	3,798	2,066	1,322	715	2,416	1,948	1,060	712
Share Based Compensation	166.7%	304	114	117	132	281	115	123	142	305	106	114	132	288	98.00	100	115	233	85.00	94.00	114	226
Cashflow From Investing	48.4%	-425	-824	-634	-1,213	-462	-632	-484	-264	-360	-671	-651	-264	-422	-731	-472	-619	-393	-489	-432	-498	-396
Cashflow From Financing	42.7%	-1,176	-2,052	-2,340	-1,289	-1,410	-1,457	-1,543	-813	-3,823	-1,886	-1,377	-1,264	-967	-787	-1,915	658	-735	-2,185	-513	-449	-1,142
Dividend Payments	-100.0%	-	888	888	890	890	823	826	828	832	798	801	803	800	641	639	642	638	568	569	568	565
Buy Backs	-12.7%	226	259	2.00	426	540	685	798	5.00	2,307	974	579	471	275	161	2.00	4.00	236	496	1.00	4.00	217

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ABT Income Statement

2024-03-31

Condensed Consolidated Statement of Earnings (Unaudited) - USD ($) shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net sales	$ 9,964	$ 9,747
Cost of products sold, excluding amortization of intangible assets	4,463	4,331
Amortization of intangible assets	472	491
Research and development	684	654
Selling, general and administrative	2,959	2,762
Total operating cost and expenses	8,578	8,238
Operating earnings	1,386	1,509
Interest expense	141	153
Interest (income)	(80)	(101)
Net foreign exchange (gain) loss	0	6
Other (income) expense, net	(111)	(111)
Earnings before taxes	1,436	1,562
Taxes on earnings	211	244
Net Earnings	$ 1,225	$ 1,318
Basic Earnings Per Common Share (in dollars per share)	$ 0.70	$ 0.75
Diluted Earnings Per Common Share (in dollars per share)	$ 0.70	$ 0.75
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares)	1,740,203	1,741,738
Dilutive Common Stock Options (in shares)	9,449	9,977
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares)	1,749,652	1,751,715
Outstanding Common Stock Options Having No Dilutive Effect (in shares)	6,892	7,332

ABT Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheet (Unaudited) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 6,284	$ 6,896
Short-term investments	367	383
Trade receivables, less allowances of $439 in 2024 and $444 in 2023	6,605	6,565
Inventories:
Finished products	4,063	3,946
Work in process	881	807
Materials	1,883	1,817
Total inventories	6,827	6,570
Prepaid expenses and other receivables	2,293	2,256
Total Current Assets	22,376	22,670
Investments	818	799
Property and equipment, at cost	22,055	21,933
Less: accumulated depreciation and amortization	11,948	11,779
Net property and equipment	10,107	10,154
Intangible assets, net of amortization	8,296	8,815
Goodwill	23,383	23,679
Deferred income taxes and other assets	7,487	7,097
Total Assets	72,467	73,214
Current Liabilities:
Trade accounts payable	4,178	4,295
Salaries, wages and commissions	1,092	1,597
Other accrued liabilities	5,220	5,422
Dividends payable	959	955
Income taxes payable	562	492
Current portion of long-term debt	2,010	1,080
Total Current Liabilities	14,021	13,841
Long-term debt	12,576	13,599
Post-employment obligations, deferred income taxes and other long-term liabilities	6,827	6,947
Commitments and Contingencies
Shareholders’ Investment:
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued	0	0
Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2024: 1,989,789,999; 2023: 1,987,883,852	24,726	24,869
Common shares held in treasury, at cost — Shares: 2024: 250,155,515; 2023: 253,807,494	(15,761)	(15,981)
Earnings employed in the business	38,011	37,554
Accumulated other comprehensive income (loss)	(8,166)	(7,839)
Total Abbott Shareholders’ Investment	38,810	38,603
Noncontrolling Interests in Subsidiaries	233	224
Total Shareholders’ Investment	39,043	38,827
Total Liabilities and Shareholders' Investment	$ 72,467	$ 73,214

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, MÃƒÂ©niÃƒÂ¨re's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

CEO	Mr. Robert B. Ford
WEBSITE	abbott.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	65535

Abbott Laboratories Frequently Asked Questions

What is the ticker symbol for Abbott Laboratories? What does ABT stand for in stocks?

ABT is the stock ticker symbol of Abbott Laboratories. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Abbott Laboratories (ABT)?

As of Wed May 08 2024, market cap of Abbott Laboratories is 182.56 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABT stock?

You can check ABT's fair value in chart for subscribers.

What is the fair value of ABT stock?

You can check ABT's fair value in chart for subscribers. The fair value of Abbott Laboratories is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Abbott Laboratories is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ABT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Abbott Laboratories a good stock to buy?

The fair value guage provides a quick view whether ABT is over valued or under valued. Whether Abbott Laboratories is cheap or expensive depends on the assumptions which impact Abbott Laboratories's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABT.

What is Abbott Laboratories's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, ABT's PE ratio (Price to Earnings) is 32.45 and Price to Sales (PS) ratio is 4.53. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Abbott Laboratories's stock?

In the past 10 years, Abbott Laboratories has provided 0.122 (multiply by 100 for percentage) rate of return.